Test Price
2,800 AED✅ Home Collection Available
MYO1A Gene Autosomal Dominant Deafness Type 48 (DFNA48) Genetic Test
2,800 AED · DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% diagnostic sensitivity – full MYO1A gene coverage via NGS, interpreted by board‑certified clinical geneticists.
- Premium Logistics: Paid hospital‑grade home collection with ISO‑certified cold‑chain transport. VIP mobile phlebotomy available 8 AM‑11 PM.
- Clinical Guidance: Tele‑phonic post‑test clinical result interpretation and genetic counselling support.
- Insurance: Direct billing verification through WhatsApp: +971 54 548 8731.
DHA Licensed Facility: 1143 · ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)
Test Overview & Methodology
The MYO1A DFNA48 NGS test diagnoses autosomal dominant non‑syndromic hearing loss by sequencing the entire MYO1A gene. This analysis detects mutations responsible for inherited hearing loss, enabling precise diagnosis and informed genetic counselling.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | NGS full‑gene sequencing (99.9% sensitivity) | Single‑gene Sanger (targets known hotspots only) |
| Method | Illumina® platform + CNV analysis | PCR‑based cascading screening |
| Speed | Report in 3–4 weeks | Often >6 weeks with incomplete resolution |
| Clinical Integration | Includes post‑test genetic counselling | Report only, no interpretation |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasise that a genetic result must always be correlated with the full audiologic and family history. The MYO1A test provides a definitive molecular diagnosis for DFNA48; however, negative results do not exclude other genetic forms of hearing loss. Our team is here to guide you through the implications, ensuring every result is understood in the correct clinical context.”
— Lina Osama Zaki Quteineh, DHA License 9294403
Advisory: Medication and Treatment Precautions
Do not discontinue, modify, or initiate any medication, hearing aid, or treatment without direct consultation with your treating physician. This genetic test does not replace clinical management for hearing loss.
Exclusion Criteria and Emergency Red Flags
- Exclusion Criteria: Individuals who have not received mandatory pre‑test genetic counselling; patients unwilling to share detailed pedigree or clinical history; individuals under 18 years without legal guardian consent (per Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Emergency Red Flags (seek immediate ENT/ER care): Sudden severe hearing loss with vertigo or tinnitus; acute ear pain with discharge; any neurological signs (facial weakness, imbalance) – this test is not an emergency diagnostic tool.
Patient FAQ & Clinical Guidance
1. What is the accuracy of the MYO1A NGS test?
This test achieves over 99.9% analytical sensitivity and specificity for MYO1A variants, making it the gold standard for confirming DFNA48 autosomal dominant deafness in symptomatic individuals. All variants are classified according to ACMG guidelines, and the report includes clinical interpretation to rule out other syndromic forms.
2. What samples are accepted and how is home collection arranged?
You can provide whole blood (EDTA tube), extracted DNA, or a single drop of blood on an FTA card. Our VIP phlebotomist reaches your home or office between 8 AM and 11 PM daily. All specimens are transported in ISO‑validated cold‑chain containers, ensuring DNA integrity until processing at our DHA‑licensed facility.
3. How is my genetic data protected under UAE law?
All personal and genomic data are processed in strict compliance with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your sample is coded and stored securely; data is never shared without your explicit consent.
UAE Regulatory & Data Privacy Adherence
Your genetic data is processed in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your sample is coded, stored in a secure biobank for a limited period, and never shared without your explicit consent. DNA Labs UAE adheres to all DHA healthcare advertising regulations and ISO 9001:2015 certified processes.
Clinical & Logistical Metadata
| Test Name | MYO1A Gene Autosomal Dominant Deafness Type 48 (DFNA48) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card. VIP mobile phlebotomy available daily 8 AM–11 PM. |
| Methodology Used | Next‑Generation Sequencing (NGS) with CNV analysis on Illumina platform |
| ICD‑10‑CM Code | Z13.79 |
| LOINC Code | 21674-2 |
| DHA Facility License & Laboratory Address | DHA License 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians